Advertisement
Supplier News
Subscribe to Supplier News

The Lead

PhosImmune, PureMHC Working Together on Cancer Immunotherapies

October 22, 2014 1:28 pm | News | Comments

PhosImmune Inc. and PureMHC LLC announced they have entered into a license and collaboration agreement to develop novel antibody-based immunotherapies designed to target cancers. Read more...

Biogen Slides as MS Drug Linked to Inflammation

October 22, 2014 1:20 pm | News | Comments

Shares of Biogen Idec slumped 8% after the pharmaceutical said a patient who took its newest...

Study Finds Drugs Still in Recalled Supplements

October 22, 2014 11:48 am | by Lindsey Tanner, AP Medical Writer | News | Comments

Dietary supplements containing potentially...

12,000 Boxes of Pain Relief Tablets Are Being Recalled

October 22, 2014 10:20 am | News | Comments

12,000 boxes of pain relief tablets sold at are being recalled because the cartons contain a...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | News | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

NewLink Genetics, Genentech Enter Into Exclusive Worldwide License

October 20, 2014 10:44 am | News | Comments

NewLink Genetics Corp., a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's IDO pathway inhibitor. Read more...

Sanofi, Regeneron Announce Phase 3 Study of Atopic Dermatitis Drug

October 20, 2014 10:32 am | News | Comments

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. Read more..

Advertisement

Takeda, Orexigen Announce Availability of Weight-Management Drug

October 20, 2014 10:25 am | News | Comments

Takeda and Orexigen jointly announced that Contrave (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Read more...                 

FDA Votes to Keep Boxed Warning on Chantix

October 17, 2014 10:26 am | News | Comments

Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information. Read more...

MIT, MGH Partner to Address Clinical Medicine Challenges

October 16, 2014 1:08 pm | News | Comments

A novel partnership between MIT and Massachusetts General Hospital (MGH) is addressing three major challenges in clinical medicine. Read more...                                          

Eli Lilly's Lechleiter Honored as Watanabe Life Sciences Champion of the Year

October 16, 2014 12:43 pm | News | Comments

BioCrossroads awarded John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, with the August M. Watanabe Life Sciences Champion of the Year Award, a prestigious honor named in tribute to BioCrossroads' late first Chairman. Read more...

Moderna, Sweden Universities Collaborate on Drug Discovery

October 16, 2014 10:48 am | News | Comments

Moderna Therapeutics announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics(TM) enable the in vivo production of both intracellular proteins and secreted proteins. Read more...

Advertisement

Noven Announces Menopause Drug's Effects on Weight, Sexual Function

October 15, 2014 1:33 pm | News | Comments

Noven Pharmaceuticals Inc., announced the publication of data on the effects of low-dose mesylate salt of paroxetine (LDMP), marketed as Brisdelle (paroxetine) capsules, 7.5 mg, in Menopause, the peer-reviewed, scientific journal of The North American Menopause Society (NAMS). Read more...

Clinical Conductor Takes Aim at Optimizing Oncology Clinical Trials

October 15, 2014 10:38 am | News | Comments

 The team behind Clinical Conductor is proud to announce brand new enhancements to the industry-leading CTMS. This first oncology focused release of several in the coming quarters adds a multitude of advanced features and functionalities designed to optimize the management and execution of oncology studies at organizations of all sizes and makeups.Read more...

Selecta, JDRF, Sanofi Collaborate on SVP Immunotherapy for Type 1

October 15, 2014 10:31 am | News | Comments

Selecta Biosciences and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop an SVP immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. Read more...

Pfizer Gets FDA Acceptance of Palbociclib

October 13, 2014 2:35 pm | News | Comments

Pfizer Inc. announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). Read more...                                

FDA Approves First Drug-Coated Angioplasty Balloon Catheter for PAD

October 10, 2014 3:23 pm | News | Comments

The U.S. Food and Drug Administration approved the Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB). Read more...                              

Advertisement

Gilead Sciences' Once-Daily Hepatitis C Drug Approved by FDA

October 10, 2014 3:02 pm | News | Comments

Gilead Sciences, Inc. announced that the U.S. FDA has approved Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Read more...

NIH Invests Nearly $32M to Increase Utility of Biomedical Research Data

October 9, 2014 3:26 pm | News | Comments

Wide-ranging National Institutes of Health grants announced will develop new strategies to analyze and leverage the explosion of increasingly complex biomedical data sets, often referred to as Big Data. Read more...

Endo Intl to Buy Auxilium in Deal Worth $2.6B

October 9, 2014 3:09 pm | News | Comments

Ireland's Endo International is planning to buy Auxilium Pharmaceuticals in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid. The Auxilium board embraced the latest offer but its shareholders get to vote on it. Read more...

Purdue Pharma Launches Smaller Dosage of Chronic Pain Patch

October 9, 2014 3:03 pm | News | Comments

Purdue Pharma L.P. announced the U.S. commercial launch of the new 7.5 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII. Five strengths of Butrans are now available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. Read more...

Amgen Says Version of Humira Meets Study Goal

October 9, 2014 10:42 am | by The Associated Press | News | Comments

Amgen said that its version of Humira, the best-selling drug in the world, worked as well as the original medication in a late-stage clinical trial. Read more...                             

New COPD Inhalation Spray Now Available in U.S. Pharmacies

October 8, 2014 12:58 pm | News | Comments

Boehringer Ingelheim announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. Read more...                               

C3BS Gets Preferred Access from Mayo Clinic

October 8, 2014 10:58 am | News | Comments

Cardio3 BioSciences (C3BS), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announced the signing of a preferred access agreement with Mayo Clinic. Read more...

Manzo Pharmaceuticals' Probiotic Will Not Need FDA Approval

October 7, 2014 3:05 pm | News | Comments

Manzo Pharmaceuticals Inc. announced that after discussions with the FDA, it has been determined that its long lasting lactose digestive aid, Lacto-Freedom, will not need FDA approval to be released to the public. Read more...           

Icon Bioscience Reports Last Patient Out in Phase 3 Cataract Study

October 6, 2014 3:30 pm | News | Comments

Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics, announced that the last patient has completed treatment in its pivotal Phase 3 study of IBI-10090. Read more...

AbbVie's Humira Receives FDA Approval for JIA

October 6, 2014 3:04 pm | News | Comments

AbbVie announced that the FDA has approved the extension of the Humira indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. Read more...

Actavis Buying Durata Therapeutics for $616.4

October 6, 2014 10:39 am | News | Comments

Specialty pharmaceutical company Actavis is buying Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. Read more...                                    

Sanofi Signs 15-Year Supply Agreement for Wearable Injectors with Unilife

October 6, 2014 9:47 am | News | Comments

Unilife Corporation, a developer and supplier of injectable drug delivery systems, announced the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading